Scand Immun Jol: Anti-p53 antiantibodies in the blood as a diagnostic biomarker for colorectal cancer.

Serum autoantibodies of tumor-related antigens are a promising biomarker for cancer diagnosis.
this review summarizes the available evidence related to the diagnostic potential of autoantibodies studied in the context of colorectal cancer (CRC).
we conducted systematic literature searches in three databases (PubMed, Cochrane Library and Embase).
reviewed data on 145 autoantibodies published in 80 articles.
, anti-p53 antibodies are the most commonly studied autoantibodies, so we meta-analyzed anti-p53 antibodies in 24 articles.
based on the cut-off value used to determine the positive anti-p53 antibody, we divided the study we included into five groups.
due to the threshold effect in Group 4 and 5, the non-threshold effect in Group 1 and Group 2, the Number of Fixed Effect Model (Mantel-Haenszel) is used for centralized analysis of Group 3.
group 3, which determined the boundary value based on the p53 antibody titer index value, consisted of 5 articles, including 733 CRC patients and 172 control groups (126 healthy people and 46 patients with benign diseases).
results, the aggregated sensitivity, specificity, positive like-like ratio, negative like-like ratio, diagnostic probability ratio and the combined area under the receiver operating characteristic shadcurve were 0.21, 0.99, 12.26, 0.80, 15.46 and 0.87, respectively.
serum anti-p53 self-antibody can potentially help distinguish BETWEEN CRC and a healthy control group or benign disease, but due to low sensitivity, it should be used in combination with other indicators.
in summary, our research provides insight into the best combination of different tumor-related antigens or autoantibodies for diagnosis of CRC.
.